Catalyst Pharmaceutical Partners, Inc. (CPRX: Quote) said Thursday that it has priced an underwritten offering of 6 million units, with each unit consisting of one share of its common stock and a warrant to purchase up to one share of its common stock, at a public offering price of $0.80 per unit.
Catalyst expects to receive net proceeds of about $4.0 million, not including any cash proceeds from a future exercise of the warrants, after deducting the underwriting discount and estimated offering expenses. The warrants will have a 5-year term and an exercise price equal to $1.04 per share.
The offering is expected to close on May 30.
The proceeds of this offering will be used: to fund the activities necessary to support the submission of an NDA for CPP-109 for FDA approval and to begin to prepare for the commercial launch of CPP-109, assuming that the data from the currently ongoing Phase II(b) trial are compelling and the FDA accepts an NDA submitted by Catalyst for CPP-109 based on the data from the Phase II(b) trial; to manufacture sufficient CPP-115 for use in one or more future safety and/or proof-of-concept studies of CPP-115; and for general corporate purposes.
Click here to receive FREE breaking news email alerts for Catalyst Pharmaceutical Partners Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org